Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib in Asian patients with advanced solid tumors
NCT02699606Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2016
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of erdafitinib in non-small cell lung cancer (NSCLC), urothelial carcinoma (UC), esophageal cancer and 1 more, sponsored by Janssen Pharmaceutical. Primary endpoint: Objective Response Rate at 2 years. Started Jul 2016; status: completed.
02
Drugs
erdafitinib
03
Conditions
non-small cell lung cancer (NSCLC)urothelial carcinoma (UC)esophageal cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02699606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02699606.